Alimera Sciences Inc (ALIM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Alimera Sciences Inc (ALIM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9806
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alimera Sciences Inc (Alimera) is a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s products include Iluvien, an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabetic macular edema (DME) in patients who have been previously treated with corticosteroids and did not show any clinically significant increase in intraocular pressure (IOP). Iluvien is also prescribed for treatment of early-and late-stage diseases such as wet and dry age-related macular degeneration (AMD) and retinal vein occlusion. The company distributes its products in France, Austria, Portugal, the Czech Republic, Denmark, Finland, Germany, Spain, the UK and others. Alimera is headquartered in Alpharetta, Georgia, the US.

Alimera Sciences Inc (ALIM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alimera Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alimera Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Alimera Sciences Enters into Distribution Agreement with Horus Pharma 11
Alimera Sciences Enters into Distribution Agreement with Brill Pharma 12
Alimera Sciences Enters into Distribution Agreement with MEAgate 13
Alimera Sciences Enters into Distribution Agreement with SIFI for Iluvien 14
Alimera Sciences Enters into Distribution Agreement with Knight Therapeutics 15
Alimera Sciences Enters Into Distribution Agreement With Specialised Therapeutics For Iluvien 16
Equity Offering 17
Alimera Sciences Plans to Raise up to USD100 Million in Public Offering of Securities 17
Alimera Sciences Raises USD1.2 Million in Public Offering of Shares 18
Alimera Sciences Raises USD26.5 Million in Public Offering of Shares 19
Alimera Sciences Raises USD0.8 Million in Private Placement of Shares 21
Alimera Sciences Raises USD50 Million in Private Placement of Preferred Stock 22
Alimera Sciences Raises USD35 Million in Public Offering of Shares 24
Alimera Sciences Completes Private Placement Of Shares For US$37.5 Million 25
Alimera Sciences Completes Private Placement Of Units For US$40 Million 26
Acquisition 28
Alimera Sciences Mulls for Sale 28
Alimera Sciences Inc – Key Competitors 29
Alimera Sciences Inc – Key Employees 30
Alimera Sciences Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 05, 2018: Alimera Sciences reports third quarter 2018 results 32
Jul 31, 2018: Alimera Sciences Reports Second Quarter 2018 Results 34
May 02, 2018: Alimera Sciences Reports First Quarter 2018 Results 36
Feb 28, 2018: Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results 38
Nov 01, 2017: Alimera Sciences Reports Third Quarter 2017 Financial Results 40
Aug 02, 2017: Alimera Sciences Reports Second Quarter 2017 Financial Results 42
May 08, 2017: Alimera Sciences Reports First Quarter 2017 Financial Results 44
Mar 01, 2017: Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results 46
Corporate Communications 48
Jun 21, 2018: Alimera Sciences Names Mary T. Szela As Board Director 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alimera Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alimera Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Alimera Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alimera Sciences Enters into Distribution Agreement with Horus Pharma 11
Alimera Sciences Enters into Distribution Agreement with Brill Pharma 12
Alimera Sciences Enters into Distribution Agreement with MEAgate 13
Alimera Sciences Enters into Distribution Agreement with SIFI for Iluvien 14
Alimera Sciences Enters into Distribution Agreement with Knight Therapeutics 15
Alimera Sciences Enters Into Distribution Agreement With Specialised Therapeutics For Iluvien 16
Alimera Sciences Plans to Raise up to USD100 Million in Public Offering of Securities 17
Alimera Sciences Raises USD1.2 Million in Public Offering of Shares 18
Alimera Sciences Raises USD26.5 Million in Public Offering of Shares 19
Alimera Sciences Raises USD0.8 Million in Private Placement of Shares 21
Alimera Sciences Raises USD50 Million in Private Placement of Preferred Stock 22
Alimera Sciences Raises USD35 Million in Public Offering of Shares 24
Alimera Sciences Completes Private Placement Of Shares For US$37.5 Million 25
Alimera Sciences Completes Private Placement Of Units For US$40 Million 26
Alimera Sciences Mulls for Sale 28
Alimera Sciences Inc, Key Competitors 29
Alimera Sciences Inc, Key Employees 30
Alimera Sciences Inc, Subsidiaries 31

List of Figures
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alimera Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Alimera Sciences Inc (ALIM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hosken Consolidated Investments Ltd (HCI):企業の財務・戦略的SWOT分析
    Hosken Consolidated Investments Ltd (HCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Sirius XM Holdings Inc.:戦略・SWOT・企業財務分析
    Sirius XM Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Sirius XM Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • DesignMedix Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary DesignMedix Inc (DesignMedix) is a biotechnology company that develop drugs to overcome drug resistance in multiple diseases such as malaria and diarrhea. The company develops malaria cure drugs, malaria preventive drugs and anti-bacterial drugs. It develops DM1157, a drug candidate that pro …
  • Abengoa SA (ABG):電力:M&Aディール及び事業提携情報
    Summary Abengoa SA (Abengoa) is an applied engineering and equipment manufacturer. It employs novel technological solutions for sustainability in infrastructures, energy and water sectors. The company provides integrated project solutions. Abengoa’s solutions include engineering, and operation and m …
  • Contact Energy Ltd (CEN):電力:M&Aディール及び事業提携情報
    Summary Contact Energy Ltd (Contact Energy) is an energy company that generates electricity and sells electricity, natural gas and liquefied petroleum gas to customers. It generates electricity from various sources of energy including thermal, hydro and geothermal sources of energy. It supplies elec …
  • VWR Corp (VWR)-医療機器分野:企業M&A・提携分析
    Summary VWR Corp (VWR) is a medical equipment company that distributes laboratory products, and provides services and solutions. The company offers product such chemicals, reagents, consumables, durable products, scientific equipment and instruments. It offers products in the areas of research and d …
  • Inova Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Inova Diagnostics Inc (Inova), a subsidiary of Werfen Life Group SAU is a medical device company that develops and commercializes new autoimmune technologies and diagnostic markers. The company's diagnostic reagent products include quanta flash used for semi-quantitative determination of aut …
  • Infinera Corporation:戦略・SWOT・企業財務分析
    Infinera Corporation - Strategy, SWOT and Corporate Finance Report Summary Infinera Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • CWC Energy Services Corp (CWC):石油・ガス:M&Aディール及び事業提携情報
    Summary CWC Energy Services Corp (CWC), formerly CWC Well Services Corp, is an oilfield servicing company that provides drilling rigs, service rigs, coil tubing and well testing services in the Western Canadian Sedimentary Basin. The company operates through two divisions such as contract drilling a …
  • Caixa Geral de Depositos SA:企業の戦略的SWOT分析
    Caixa Geral de Depositos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Echelon Corporation (ELON):企業の財務・戦略的SWOT分析
    Echelon Corporation (ELON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Invuity Inc (IVTY):企業の財務・戦略的SWOT分析
    Summary Invuity Inc (Invuity) is a medical technology company that develops and markets advanced surgical devices for the minimally invasive and minimal access procedures. The company offers illuminated surgical retractors, single-use handheld aspiration and universal drop-in intracavity illuminator …
  • Fortis Inc (FTS):企業の財務・戦略的SWOT分析
    Summary Fortis Inc (Fortis) is an oil and gas company that provides development of assets and market capitalization programs. The company offers measurement and monitoring of environmental impacts. It also provides capital program and growth plans to meet the energy needs. Fortis support and partici …
  • Duraloy Technologies Inc:企業の戦略的SWOT分析
    Duraloy Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Europa Oil & Gas (Holdings) Plc (EOG):石油・ガス:M&Aディール及び事業提携情報
    Summary Europa Oil & Gas (Holdings) Plc (Europa Oil) is an oil and gas company that offers exploration and development services. The company's services include production and development of conventional and unconventional hydrocarbon assets. It operates its assets in East Midlands basin, Aquitain ba …
  • SSA Marine, Inc.:企業の戦略・SWOT・財務分析
    SSA Marine, Inc. - Strategy, SWOT and Corporate Finance Report Summary SSA Marine, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Bollore SA (BOL):企業の財務・戦略的SWOT分析
    Bollore SA (BOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Western Areas Limited:企業の戦略・SWOT・財務情報
    Western Areas Limited - Strategy, SWOT and Corporate Finance Report Summary Western Areas Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • AT&T Inc:企業のM&A・事業提携・投資動向
    AT&T Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AT&T Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Compagnie d’Entreprises CFE SA:企業の戦略・SWOT・財務情報
    Compagnie d'Entreprises CFE SA - Strategy, SWOT and Corporate Finance Report Summary Compagnie d'Entreprises CFE SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆